DMAC - DiaMedica Therapeutics Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD

DiaMedica Therapeutics Inc.

2 Carlson Parkway
Suite 260
Minneapolis, MN 55447
United States
763-496-5454
http://www.diamedica.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees9

Key Executives

NameTitlePayExercisedYear Born
Mr. Rick Pauls M.B.A., MBAPres, CEO & Director492.4kN/A1971
Mr. Scott B. Kellen C.A.CFO & Company Sec.280.96kN/A1965
Dr. Todd A. VerdoornChief Scientific Officer266.53kN/A1962
Mr. Edward B. RadyChief Commercial AdvisorN/AN/A1949
Dr. Dennis D. Kim M.D., MBAConsulting Chief Medical OfficerN/AN/A1970
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of recombinant proteins for the treatment of kidney and neurological diseases. Its lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase Ib clinical trials for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase II REMEDY trials for the treatment of patients with acute ischemic stroke. The company is also developing DM199 for the treatment vascular dementia; and DMDx, a diagnostic tool to measure human tissue kallikrein-1 levels. It has a license and collaboration agreement with Ahon Pharmaceutical Co Ltd. to develop and commercialize DM199 for acute ischemic stroke. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.

Corporate Governance

DiaMedica Therapeutics Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.